We believe that analyzing legal precedents by reference to the stage of drug or device development at which the setback occurs may yield useful insights and assist in risk mitigation and insurance strategies.
In this webinar we will discuss:
- Overview and analysis of trends in decisions involving life sciences companies with products at two distinct stages of development—pre- and post-FDA approval and takeaways that can help guide disclosure approaches
- Recent cases and what those reveal about the events that can draw a lawsuit
- Insight into the D&O Insurance underwriters' reaction to the volatile life science shareholder litigation landscape
Sara Brody, Partner, Sidley
Kristin Kraeger, Managing Director, Financial Services Group, Aon
WHY IT MATTERS
When you are in an industry that is a target of the shareholder plaintiff's bar, navigating your D&O renewal must be thoughtful and multifaceted.
Presented by Sidley's Securities and Shareholder Litigation practice & Aon's Financial Services group.
View the Securities Class Actions in the Life Sciences Sector – 2018 Annual Survey.
Sidley Austin LLP is an accredited MCLE provider in IL, NY and CA. CLE Credit for this program is pending.
For more information, contact firstname.lastname@example.org.